bluuebunny/crossref_metadata_2025_split huggingface dataset:
Predictive models in diagnosing indolent cancer
Authors: Bangma Chris H. , Roobol Monique J. , Steyerberg Ewout W. 
Published: March 2010

AbstractThe early detection of prostate cancer has led to the increased incidence of tumors that are unlikely to become symptomatic during life: so‐called indolent cancers. The ability to predict indolent prostate cancer is needed to avoid over treatment by unnecessary invasive therapies and to select men for active surveillance. For this report, the currently available nomograms that predict these low‐risk tumors were reviewed. Many of these nomograms were based on clinical patient series, thus, their general application is restricted. Those nomograms based on screening series of the general population need further validation before generalized application is feasible. Cancer 2009;115(13 suppl):3100–6. © 2009 American Cancer Society.
Predictive models in external beam radiotherapy for clinically localized prostate cancer
Authors: Roach Mack , Waldman Fred , Pollack Alan 
Published: March 2010

AbstractPredictive models are being used increasingly in effort to allow physician and patient expectations to be aligned with outcomes that are based on available data. Most predictive models for men who receive external beam radiotherapy for clinically localized prostate cancer are based on Gleason score, clinical tumor classification, and prostate‐specific antigen (PSA) levels. More sophisticated models also have been developed that incorporate treatment‐related variables, such as the dose of radiation and the use of androgen‐deprivation therapy. Most of the predictive models applied to prostate cancer were derived using PSA recurrence rates as the major endpoint, but clinical endpoints have been incorporated increasingly into predictive models. Biomarkers also are increasingly being added to predictive models in an effort to strengthen them. The Radiation Therapy Oncology Group (RTOG) has completed studies on a wide range of markers using tissue from 2 phase 3 trials (RTOG 8610 and 9202). To date, preliminary assessments of p53; DNA ploidy; p16/retinoblastoma 1 protein; Ki‐67; mouse double‐minute p53 binding protein homolog; Bcl‐2/Bcl‐2–associated X protein; cytosine, adenine, and guanine repeats; cyclooxygenase‐2; signal transducer and activator of transcription 3; cytochrome P450 3A4; and protein kinase A have been completed. Although they are not ready for widespread, routine use, there are reasons to believe that future models will combine these markers with traditional pretreatment and treatment‐related variables and will improve our ability to predict outcome and select the optimal treatment. Cancer 2009;115(13 suppl):3112–20. © 2009 American Cancer Society.
Genomic approaches to outcome prediction in prostate cancer
Authors: Febbo Phillip G. 
Published: March 2010

AbstractProstate cancer remains a common cause of cancer death in men. Applications of emerging genomic technologies to high‐quality prostate cancer models and patient samples in multiple contexts have made significant contributions to our molecular understanding of the development and progression of prostate cancer. Genomic analysis of DNA, RNA, and protein alterations allows for the global assessment of this disease and provides the molecular framework to improve risk classification, outcome prediction, and development of targeted therapies. In this review, the author focused on highlighting recent work in genomics and its role in evaluating molecular modifiers of prostate cancer risk and behavior and the development of predictive models that anticipate the risk of developing prostate cancer, prostate cancer progression, and the response of prostate cancer to therapy. This framework has the exciting potential to be predictive and to provide personalized and individual treatment to the large number of men diagnosed with prostate cancer each year. Cancer 2009;115(13 suppl):3046–57. © 2009 American Cancer Society.
Beta‐2‐microglobulin is an independent predictor of progression in asymptomatic multiple myeloma
Authors: Rossi Davide , Fangazio Marco , De Paoli Lorenzo , Puma Alessia , Riccomagno Paola , Pinto Valeria , Zigrossi Paola , Ramponi Antonio , Monga Guido , Gaidano Gianluca 
Published: March 2010

AbstractBACKGROUND:Although serum beta‐2 microglobulin (B2M) represents a key variable for symptomatic multiple myeloma (MM) prognostication, its role in predicting the risk of progression of asymptomatic MM to symptomatic disease has not been explored.METHODS:This study was bases on a consecutive series of 148 patients with asymptomatic MM and explored the cumulative probability of progression to symptomatic MM as the primary endpoint.RESULTS:In univariate analysis, a serum B2M level >2.5 mg/L was associated with an increased probability of disease progression (5‐year risk, 64.5%;P< .001) along with serum monoclonal component (sMC) (P< .001), urinary monoclonal component (uMC) (P< .001), and bone marrow plasma cells (BMPCs) (P< .001). In multivariate analysis, serum B2M was selected as an independent predictor of progression (hazard ratio, 3.30;P= .002). Serum B2M was combined with sMC, uMC, and BMPC to create a risk‐stratification model based on 4 groups with different risk of progression: very low (5‐year risk, 0%), low‐intermediate (5‐year risk, 19.6%), high‐intermediate (5‐year risk, 60.7%), and high (5‐year risk, 80.7%). The model that included serum B2M along with sMC, uMC, and BMPC was able to predict disease progression better than the model that was based on sMC, uMC, and BMPC without serum B2M (C statistics, 0.760 vs 0.726).CONCLUSIONS:The current results indicated that 1) serum B2M is an independent predictor of asymptomatic MM progression, and 2) serum B2M adds prognostic information when combined with the most widely used prognosticators of asymptomatic MM progression. Cancer 2010. © 2010 American Cancer Society.
A Waste‐Derived Biosurfactant for the Preparation of Templated Silica Powders
Authors: Boffa Vittorio , Perrone Daniele G. , Montoneri Enzo , Magnacca Giuliana , Bertinetti Luca , Garlasco Luisa , Mendichi Raniero 
Published: March 2010

AbstractA polymeric anionic biosurfactant isolated from urban bio‐wastes was used as a template for fabricating silica powders of pore size ranging from 4 to 30 nm by the sol‐gel reaction of tetraethylorthosilicate and 3‐aminopropyltriethoxysilane at pH 5. The morphology of the synthesized silica powders was found to depend on the size and the conformation of the biosurfactant molecules or aggregates in solution. The use of waste‐derived biosurfactants as templating agents reduces the fabrication costs and the environmental impact of mesoporous materials. At the same time, it encourages the upgrade of bio‐wastes from a costly disposal matter to a source of chemicals and therefore, of revenue.
Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: A pilot study on a series of 56 patients
Authors: Matarraz Sergio , López Antonio , Barrena Susana , Fernandez Carlos , Jensen Evan , Flores‐Montero Juan , Rasillo Ana , Sayagues José María , Sánchez Maria Luz , Bárcena Paloma , Hernandez‐Rivas Jesús María , Salvador Carlos , Fernandez‐Mosteirín Nuria , Giralt Manuel , Perdiguer Luis , Laranjeira Paula , Paiva Artur , Orfao Alberto 
Published: March 2010

AbstractA heterogeneous spectrum of immunophenotypic abnormalities have been reported in myelodysplastic syndromes (MDS). However, most studies are restricted to the analysis of CD34+ cells and/or other major subsets of CD34− cells, frequently not exploring the diagnostic and prognostic impact of immunophenotyping.Methods:We propose for the first time an immunophenotypic score (IS) based on the altered distribution and immunophenotypic features of maturing/mature compartments of bone marrow (BM) hematopoietic cells in 56 patients with MDS that could contribute to a refined diagnosis and prognostic evaluation of the disease.Results:Although MDS‐associated phenotypes were detected in reactive BM, the overall immunophenotypic profile of BM cells allowed an efficient discrimination between MDS and both normal and reactive BM, once the number and degree of severity of the abnormalities detected per patient were simultaneously considered in the proposed IS. Interestingly, increasingly higher IS were found among patients with MDS showing adverse prognostic factors and in low‐ versus high‐grade cases. The most informative prognostic factors included the number of CD34+ cells, presence of aberrant CD34−/CD117+ precursors, decreased mature neutrophils and CD34− erythroid precursors, and increased numbers of CD36−/lo erythroid precursors; in addition, the IS was an independent prognostic factor for overall survival.Conclusions:Assessment of immunophenotypic abnormalities of maturing/mature BM cells allows an efficient discrimination between MDS and both normal and reactive BM, once the number and degree of severity of the abnormalities detected are simultaneously scored. Interestingly, progressively higher IS were found among patients with MDS with adverse prognostic features and shorter overall survival. © 2010 Clinical Cytometry Society
ICI problem and compensation in MIMO SC‐FDMA system with SC‐SFBC scheme
Authors: Zhang Xiu Pei , Ryu Heung‐Gyoon 
Published: March 2010

AbstractIn this paper, we address the ICI (intercarrier interference) problem and compensation in MIMO (multiple input multiple output) SC‐FDMA (single carrier frequency division multiple access) system that exploits SC‐SFBC (single carrier‐space frequency block coding) scheme. Recently, SC‐FDMA technique has received more attention due to the low PAPR (peak to average power ratio) property. However, SC‐FDMA system is sensitive to phase noise and CFO (carrier frequency offset) which is unavoidable in wireless communication systems. Phase noise and CFO introduce CPE (common phase error) as well as ICI into the received signal and seriously degrade the system performance. Therefore, analysis and suppression of these interferences are of great importance. In this paper, we analyze the interferences in MIMO SC‐FDMA system with SC‐SFBC. Then a new ICI estimation and suppression method is proposed to suppress the interferences. Instead of directly estimating the CFO and phase noise, which is pretty difficult and complex, this algorithm exploits block‐type pilots, which is a common pilot pattern in wireless communication systems, such as LTE standard, to estimate the interferences. After that the interferences are suppressed by the inverse matrix method. Simulation results show that the system performance is significantly improved. Copyright © 2010 John Wiley & Sons, Ltd.
Safety and tolerability of once‐daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double‐blind, placebo‐controlled studies
Authors: Meulien Didier , Huizar Karin , Brecher Martin 
Published: March 2010

AbstractIntroductionExtended release quetiapine fumarate (quetiapine XR) is a new formulation that allows once‐daily dosing and a titration regimen that is simpler than that of immediate release quetiapine (quetiapine IR) and may potentially increase patients' adherence to their prescribed medication.MethodsThe tolerability of quetiapine XR was examined in an analysis of pooled data from three Phase III, double‐blind, placebo‐controlled, randomised studies with quetiapine IR as a reference treatment.ResultsThe overall incidence of adverse events (AEs) was similar for quetiapine XR (69.5%) and quetiapine IR (72.5%). Most AEs were mild to moderate in severity and in line with those observed with quetiapine IR. The more rapid dose titration of quetiapine XR did not produce any new safety concerns and was as well tolerated as the regimen for quetiapine IR.ConclusionsThe results of this pooled analysis show that quetiapine XR administered once daily is generally as well tolerated as quetiapine IR given twice daily. These data, together with the simpler dose‐titration of quetiapine XR that allowed therapeutically effective doses to be reached by Day 2, suggest that this formulation potentially may improve adherence in patients with schizophrenia. Copyright © 2010 John Wiley & Sons, Ltd.
Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004
Authors: Centorrino Franca , Ventriglio Antonio , Vincenti Alessio , Talamo Alessandra , Baldessarini Ross J. 
Published: March 2010

AbstractBackgroundWe tested the hypothesis that combinations and total daily doses of psychotropics for hospitalized patients diagnosed with major psychiatric disorders are rising.MethodsWe evaluated McLean Hospital records of 481 consecutive inpatients with DSM‐IV schizophrenia, schizoaffective, or bipolar disorders in 2004 (n = 278) or 2009 (n = 203) to compare characteristics and treatments.ResultsIn 2009, Clinical Global Impression (CGI)‐severity scores were 6% lower at intake and improved 1.7 times more than in 2004, as hospitalization‐length decreased by 12%. Polytherapy (≥ 2 psychotropics) increased in 2009 (affective or schizoaffective disorders > schizophrenia). Total psychotropics/patient (3.1–3.2) remained stable but mood‐stabilizers/patient increased markedly and antipsychotics/patient decreased somewhat in 2009. Antipsychotic‐choice (2009) ranked: quetiapine, aripiprazole, risperidone, and others; mood‐stabilizers ranked: lamotrigine, valproate, lithium, and others (1/4 off‐label). In 2009, final total antipsychotic doses (mg/day) increased by 97%, and mood‐stabilizers by 75%. Adverse‐effect rates fell by half. Factors differing independently for 2009 versus 2004 ranked: (a) more CGI improvement, (b) more mood‐stabilizers/patient, (c) lower admission CGI scores, and (c) higher total antipsychotic dose.CommentCombinations and doses of antipsychotic and mood‐stabilizing drugs for inpatients increased markedly (2004 vs. 2009) without consistent correspondence of agents/person and doses, without apparent increase in major adverse effects, and with possibly superior clinical improvement. Copyright © 2010 John Wiley & Sons, Ltd.
Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo‐controlled pilot study
Authors: Quante Arnim , Zeugmann Sara , Luborzewski Alexander , Schommer Nicole , Langosch Jens , Born Christoph , Anghelescu Ion , Wolf Juergen 
Published: March 2010

AbstractObjectiveThe use of atypical antipsychotics (AAPs) for the treatment of unipolar and bipolar depression has been more and more frequently evaluated, and aripiprazole showed positive effects in the treatment of unipolar depression. However, no placebo‐controlled studies of adjunctive aripiprazole for the treatment of bipolar depression have been performed yet.MethodsIn this prospective, double‐blind, placebo‐controlled, randomized trial, 23 inpatients with bipolar depression according to DSM‐IV criteria were included. Before randomization, patients had to be on a constant mood stabilizer treatment with lithium or valproate for at least 1 week. After inclusion, all patients were openly treated with additional citalopram and with additional aripiprazole or placebo for 6 weeks. The primary outcome parameter was the reduction in depressive symptoms according to the Hamilton Depression Rating Scale (HDRS) within 6 weeks.ResultsAfter 6 weeks of treatment, the HDRS score decreased in both groups. There was no significant difference between both the groups at any point of time with respect to the HDRS.ConclusionsDerived from this small pilot study, adjunctive aripiprazole does not seem to be a promising strategy for the acute treatment of bipolar depression. However, this lack of additional benefit seems to stem from the already good effectiveness of the control group, namely the treatment with citalopram. Copyright © 2010 John Wiley & Sons, Ltd.
Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine
Authors: Zou Yan‐Feng , Wang Yu , Liu Ping , Feng Xiao‐Liang , Wang Bin‐Yan , Zang Tong‐Hua , Yu Xin , Wei Jing , Liu Zhong‐Chun , Liu Ying , Tao Ming , Li Hui‐Chun , Li Ke‐Qing , Hu Jian , Li Ming , Zhang Ke‐Rang , Ye Dong‐Qing , Xu Xi‐Ping 
Published: March 2010

AbstractObjectiveTo explore the association of brain‐derived neurotrophic‐factor (BDNF) Val66Met polymorphism with both baseline health related quality of life (HRQOL) scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine.MethodsPatients with major depressive disorder (MDD) took fluoxetine (20 mg/day) for 6 weeks. The HRQOL was measured with the Medical Outcomes Study Short Form‐36 (SF‐36) at baseline and at 6th week. Patients were genotyped for Val66Met polymorphism of BDNF gene.ResultsThere was a significant association between social function (SF) and BDNF Val66Met polymorphism, and patients with Met/Met genotype had better SF (compared with Val/Val P = 0.004; compared with Val/Met P = 0.005). A significant association was found between improvement in SF and BDNF Val66Met polymorphism, and patients with Met/Met genotype had poorer improvement in SF (compared with Val/Val P = 0.010; compared with Val/Met P = 0.001). Similar association was found between improvement in mental component summary (MCS) and BDNF Val66Met polymorphism, and patients with Met/Met genotype had poorer improvement in MCS (compared with Val/Val P = 0.066; compared with Val/Met P = 0.006).ConclusionsThese results indicate that there may be association between BDNF Val66Met polymorphism and both baseline HRQOL (SF) scores and improvement in HRQOL (SF, MCS) scores in Chinese major depressive patients treated with fluoxetine. Copyright © 2010 John Wiley & Sons, Ltd.
Neurocognition and its influencing factors in the treatment of schizophrenia—effects of aripiprazole, olanzapine, quetiapine and risperidone
Authors: Riedel M. , Schennach‐Wolff R. , Musil R. , Dehning S. , Cerovecki A. , Opgen‐Rhein M. , Matz J. , Seemüller F. , Obermeier M. , Engel R. R. , Müller N. , Möller H.‐J. , Spellmann I. 
Published: March 2010

AbstractBackgroundTo examine influencing variables of neurocognition in patients with schizophrenia and to predict cognition during antipsychotic treatment.MethodsData were obtained from patients with an acute episode of schizophrenia participating in two double‐blind and one open label trial comparing the effects of different atypical antipsychotics on cognition. In total, 129 patients were enrolled in this analysis. Cognitive function was assessed at admission, week 4 and 8. Efficacy and tolerability were assessed weekly using the Positive and Negative Syndrome Scale (PANSS) and the Simpson Angus Sale (SAS). Patients were treated with aripirazole, olanzapine, quetiapine and risperidone. Regression analysis including mixed effect models was performed.ResultsA significant improvement in all cognitive domains was observed from baseline to week 8. Regarding the antipsychotic treatment applied quetiapine seemed to achieve the most favourable cognitive improvement. Negative and depressive symptoms, the patient's age and the concomitant and antipsychotic treatment applied were observed to significantly influence and predict neurocognition.ConclusionThe results may indicate that schizophrenia is a static disorder with trait and state dependent cognitive components especially in the memory domains. The influence of negative and depressive symptoms should be considered in daily clinical routine. Copyright © 2010 John Wiley & Sons, Ltd.
NK depletion results in increased CCL22 secretion and Treg levels in Lewis Lung Carcinoma via the accumulation of CCL22‐secreting CD11b+CD11c+ cells
Authors: Mailloux Adam W. , Clark Anna‐Maria A. , Young M. Rita I. 
Published: March 2010

AbstractTumor‐induced immune suppression involves the accumulation of suppressive infiltrates in the tumor microenvironment such as regulatory T‐cells (Tregs). Previous studies demonstrated that NK‐dependant increases in CCL22 secretion selectively recruit Tregs toward murine lungs bearing Lewis Lung Carcinoma (LLC). To extend the in vitro studies, the present studies utilized in vivo depletion of NK cells to ascertain the contribution of NK‐derived CCL22 toward total CCL22 and subsequent Treg levels in both normal and LLC‐bearing lungs. However, NK depletion had the unexpected effect of increasing both CCL22 secretion and Treg levels in the lungs of NK‐depleted LLC‐bearing mice. This was concurrent with an increase in tumor burden. Flow cytometry and a series of both immunomagnetic and FACS isolations were used to identify the CCL22‐producing cellular fractions in LLC‐bearing lungs. A novel CD11b+CD11c+ cell population was identified that accumulates in large numbers in NK‐depleted LLC‐bearing lung tissue. These CD11b+CD11c+ cells secreted large amounts of CCL22 that may overcompensate for the loss of NK‐derived CCL22 in the lungs of NK‐depleted LLC‐bearing mice. Taken together, these data suggest that NK cells play both a positive and negative role in the regulation of CCL22 secretion and, in turn, the recruitment of Tregs toward LLC‐bearing lungs.
Biomedical research of novel biodegradable copoly(amino acid)s based on 6‐aminocaproic acid and L‐proline
Authors: Zhang Weipeng , Shao Jianmin 
Published: March 2010

AbstractThe biomedical properties of novel biodegradable copoly(amino acid)s based on 6‐aminocaproic acid and L‐proline were analyzed in this article. The cytotoxicity of the copolymer films was tested in vitro using human embryonic kidney (HEK) 293 cells. The cell proliferation, cell cycle, cell apoptosis, and hemolysis of the polymers were also investigated. No significant cytotoxic response was detected statistically by cytotoxicity assay, and the results of cell apoptosis and cell cycle showed that there were no statistically significant differences in them. Generally, the cells spread and grew well on polymer film. Meanwhile, the extent of hemolysis on the polymers was acceptable. Evaluation of cytotoxicity by cell cycle and apoptosis as a supplementary assay is correspondingly discussed in this article. © 2010 Wiley Periodicals, Inc. J Biomed Mater Res, 2010
Collagen supramolecular and suprafibrillar organizations on osteoblasts long‐term behavior: Benefits for bone healing materials
Authors: Vigier Sylvain , Helary Christophe , Fromigue Olivia , Marie Pierre , Giraud‐Guille Marie‐Madeleine 
Published: March 2010

AbstractThis study compares the behavior of osteoblastic cells seeded on three structurally distinct collagen‐based materials. Adhesion and long‐term behavior were evaluated in vitro in regard to collagen scaffolds forming loose or dense fibrillar networks or exempt of fibrils. In this purpose collagen solutions at concentrations of 5 and 40 mg/mL were processed by freeze‐drying or by sol/gel fibrillogenesis to form either sponges or hydrogels. Macroscopic and microscopic images of sponges showed a light material exhibiting large pores surrounded by dense collagen walls made of thin unstriated microfibrils of 20 nm in diameter. In comparison collagen hydrogels are more homogeneous materials, at 5 mg/mL the material consists of a regular network of cross‐striated collagen fibrils of 100 nm in diameter. At 40 mg/mL the material appears stiffer, the ultrastructure exhibits cross‐striated collagen fibrils packed in large bundles of 300–800 nm of width. Human osteoblastic cells seeded on top of the 5 mg/mL matrices exhibit a squared shaped osteoblast‐like morphology over 28 days of culture and express both alkaline phosphatase and osteocalcin. Osteoblastic cells seeded on top of sponges or of 40 mg/mL matrices exhibit both flat and elongated resting‐osteoblast morphology. Osteoblastic cells have mineralized the three collagen‐based materials after 28 days of culture but collagen sponges spontaneously mineralized in absence of cells. These results highlight, in an in vitro cell culture approach, the benefit of fibrils and of dense fibrillar networks close to in vivo‐like tissues, as positive criteria for new bone tissue repair materials. © 2010 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2010